Published in Vaccine Weekly, July 25th, 2001
J.A. Whittum-Hudson described the difficulties of three decades of antichlamydia vaccine research that have yet to produce a candidate that can protect against heterologous challenge or infectious challenge at more than one site.
"The majority of experimental anti-chlamydial vaccines to date have targeted the chlamydial major outer membrane protein (MOMP)," wrote Whittum-Hudson and colleagues. "Many MOMP-directed vaccine candidates have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.